Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 1 year and \</= 10 years~* Weight over 10kg~* Fever \>38 degrees C (tympanic) or history of fever in the last 24 hours~* P. falciparum parasitaemia \<500 000/µl~* Normal G6PD enzyme function~Exclusion Criteria:~* Enrolled in another study~* Evidence of severe illness/ danger signs~* Known allergy to study medications~* Haemoglobin \< 8g/dL)~* Started menstruation~* Pregnancy or breastfeeding~* Primaquine taken within the last 4 weeks~* Blood transfusion within the last 90 days~* Non-falciparum malaria co-infection

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Non-active drug
- Low dose primaquine (PQ1) (Type: EXPERIMENTAL): Lowest experimental dose of primaquine base: 0.1mg/kg
- Intermediate dose primaquine (PQ2) (Type: EXPERIMENTAL): Intermediate experimental dose of primaquine base: 0.4mg/kg
- Reference dose primaquine (PQ-R) (Type: ACTIVE_COMPARATOR): WHO-recommended dose of primaquine base: 0.75mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).